Straits Times Index
3,316.56 -6.06 (-0.18%) Nikkei
38,646.11 -457.11 (-1.17%) Hang Seng
18,608.94 -259.77 (-1.38%) FTSE 100
8,308.95 -30.28 (-0.36%) Bitcoin USD
67,310.17 -1,114.78 (-1.63%) CMC Crypto 200
1,419.71 -48.39 (-3.30%)
LLY May 2024 615.000 put
| Previous close | 0.0100 |
| Open | 0.0100 |
| Bid | 0.0000 |
| Ask | 4.3000 |
| Strike | 615.00 |
| Expiry date | 2024-05-24 |
| Day's range | 0.0100 - 0.0100 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
- Yahoo Finance Video
Stocks open in the green, Dow hopeful to claw back losses
Stocks (^DJI, ^IXIC, ^GSPC) edge higher at Friday's open, hoping to reclaim slight losses ahead of the long Memorial Day Weekend. Yahoo Finance Senior Markets Reporter Jared Blikre joins the Morning Brief to examine the market direction and this morning's across-the-board sector gains. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
PR NewswireLilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines
Eli Lilly and Company (NYSE: LLY) announced today that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company's total investment in this site from $3.7 billion to $9 billion. This expansion will enhance Lilly's capacity to manufacture active pharmaceutical ingredients (API) for Zepbound® (tirzepatide) injection and Mounjaro® (tirzepatide) injection so that more adults with chronic diseases like obesity and ty
PR NewswireLilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a rearranged during transfection [RET] inhibitor), olomorasib (an investigational KRAS G12C inhibitor) and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 in Chicago.
